140 related articles for article (PubMed ID: 24866673)
1. A safe pair of hands.
Dean E
Nurs Stand; 2014 Jun; 28(39):61. PubMed ID: 24866673
[TBL] [Abstract][Full Text] [Related]
2. European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287.
Flavell DJ; Flavell SU; Sullivan R
Lancet; 2003 Oct; 362(9393):1415. PubMed ID: 14585646
[No Abstract] [Full Text] [Related]
3. Differences between medical devices and drugs.
Browning P
Br J Nurs; 2014 Jun 26-Jul 9; 23(12):S28-9. PubMed ID: 25075388
[No Abstract] [Full Text] [Related]
4. UK minister lobbied EU for lighter regulation of drugs and devices.
Cohen D
BMJ; 2016 Jun; 353():i3357. PubMed ID: 27307393
[No Abstract] [Full Text] [Related]
5. Change, but not in dollar bills. FDA needs more than money to fix problems: Congress.
Lubell J
Mod Healthc; 2008 Feb; 38(5):10-1. PubMed ID: 18320666
[No Abstract] [Full Text] [Related]
6. Product safety and business interests: deja vu..
Rijswijk L
Ostomy Wound Manage; 2005 Feb; 51(2):8-9. PubMed ID: 15699549
[No Abstract] [Full Text] [Related]
7. The Canadian perspective: trends in drug and medical device class actions in Canada.
Vernon W
Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
[No Abstract] [Full Text] [Related]
8. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
Mottes LM
Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
[No Abstract] [Full Text] [Related]
9. Drug assessment: UK style.
Drug Ther Bull; 2013 Dec; 51(12):141-4. PubMed ID: 24336496
[TBL] [Abstract][Full Text] [Related]
10. Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?
Wang B; Kesselheim AS
JAMA; 2016 Mar; 315(9):857-8. PubMed ID: 26934246
[No Abstract] [Full Text] [Related]
11. Shrinking waters in the safe harbor: has Integra Lifesciences v. Merck turned the tide by narrowing available exempted infringing uses?
Davison AM
Food Drug Law J; 2004; 59(1):79-92. PubMed ID: 15190926
[No Abstract] [Full Text] [Related]
12. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
Maruyama H; Kondo T
Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
[TBL] [Abstract][Full Text] [Related]
13. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
14. Why doctors should worry about preemption.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
[No Abstract] [Full Text] [Related]
15. Ejecting the FDA from the courtroom.
Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
[No Abstract] [Full Text] [Related]
16. Congress Considers Legislation on "21st Century Cures".
Consult Pharm; 2015 Jul; 30(7):424. PubMed ID: 26173195
[No Abstract] [Full Text] [Related]
17. Medicines regulation and the pharmaceutical industry.
Breckenridge A; Woods K
BMJ; 2005 Oct; 331(7520):834-6. PubMed ID: 16210285
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
19. The 21st century cures act: Opportunities and challenges.
Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909
[TBL] [Abstract][Full Text] [Related]
20. Add-ons ensure Cures Act easy lame-duck passage.
Muchmore S
Mod Healthc; 2016 Dec; 46(49):10. PubMed ID: 30399255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
